May 4, 2022 (Global News Distribution) -

NDA Partners General Manager, Eric Fish, announced today that Joseph Rosenthal, MD, a board certified Pediatric Hematologist/Oncologist and expert in the field of hematopoietic stem cell transplantation, has joined the company as an Expert Consultant. Dr. Rosenthal has been associated with City of Hope for more than 20 years where he led the Pediatric Hematology/Oncology program and served as the Endowed Chair of the Department of Pediatrics.

NDA Partners General Manager, Eric Fish, announced today that Joseph Rosenthal, MD, a board certified Pediatric Hematologist/Oncologist and expert in the field of hematopoietic stem cell transplantation, has joined the company as an Expert Consultant. Dr. Rosenthal has been associated with City of Hope for more than 20 years where he led the Pediatric Hematology/Oncology program and served as Endowed Chair of the Department of Pediatrics. Prior to these roles, he was a member of the leadership team of the Pediatric Hematology/Oncology/Bone Marrow Transplant Program at the Children’s Hospital of Orange County, California. He also served as a member of the Pediatric Oncology Faculty of Rambam Medical Center in Haifa, Israel and Pediatric Hematology and Oncology Faculty of the Soroka Medical Center in Beer Sheba, Israel.

Dr. Rosenthal’s research focuses on developing modalities that offer reduced organ toxicity, such as incorporation of total marrow and lymphoid irradiation (TMLI) as an alternative for total body irradiation (TBI) and investigating cord blood units and haplo-identical transplants to expand the donor pool for patients who lack related or unrelated matched donors. He is actively involved in the development of HCT as a treatment for sickle cell disease and developing gene-therapy modalities for genetic disorders. He serves as an investigator on clinical trials sponsored by the Pediatric Bone Marrow Transplant (BMT) Consortium and the BMT Clinical Trial Network. According to Dr. Ellen Feigal, Manager of NDA Partners’ biologics practice, “Dr. Rosenthal’s extensive clinical and research experience in the field of pediatric hematopoietic stem cell transplantation will be valuable to our clients developing therapies for pediatric patients. ”

Dr. Rosenthal earned his medical degree from Sackler School of Medicine at Tel Aviv University, Tel Aviv, Israel, master’s degree in health care management from Harvard School of Public Health, and bachelor’s degree from Hebrew University, Jerusalem, Israel. He completed his residency at the Soroka Medical Center, Beer Sheba, Israel and fellowship in Pediatric Hematology/Oncology at the University of Colorado School of Medicine in Denver, Colorado and Pediatric Cancer Research and Bone Marrow Transplantation at the Children’s Hospital of Orange County, Orange, California.

About NDA Partners
NDA Partners, a ProPharma Group company, is a life sciences management consulting and contract development organization focused on providing product development and regulatory services to the pharmaceutical, biotechnology, and medical device industries worldwide. The highly experienced Expert Consultants in NDA Partners include three former FDA Center Directors; the former Chief Executive Officer and Chief Science Officer at the United States Pharmacopeial Convention (USP); an international team of more than 100 former pharmaceutical industry and regulatory agency senior executives; and an extensive roster of highly proficient experts in specialized areas including nonclinical development, toxicology, pharmacokinetics, CMC, medical device design control and quality systems, clinical development, regulatory submissions, and development program management. Services include product development and regulatory strategy, product development program design and management, expert consulting, functional teams, project-based solutions, and clinical trial design and management.

Contact
Eric Fish, General Manager
Office: 540-738-2550
FishEric@ndapartners.com